Select Publications
Journal articles
2022, 'Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review', Cancers, 14, http://dx.doi.org/10.3390/cancers14040920
,2022, 'Epigenetic Therapies and Biomarkers in Breast Cancer', Cancers, 14, http://dx.doi.org/10.3390/cancers14030474
,2022, 'Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing', Breast Cancer Research and Treatment, 191, pp. 501 - 511, http://dx.doi.org/10.1007/s10549-021-06456-5
,2022, 'Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status', Drug Design, Development and Therapy, 16, pp. 2933 - 2948, http://dx.doi.org/10.2147/DDDT.S380925
,2022, '211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study', Annals of Oncology, 33, pp. S633 - S634, http://dx.doi.org/10.1016/j.annonc.2022.07.250
,2021, 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study', Annals of Oncology, 32, pp. 1571 - 1581, http://dx.doi.org/10.1016/j.annonc.2021.09.015
,2021, 'Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-25422-9
,2021, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', Genome Medicine, 13, http://dx.doi.org/10.1186/s13073-021-00885-z
,2021, 'Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models', Breast Cancer Research, 23, http://dx.doi.org/10.1186/s13058-021-01461-4
,2021, 'Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-25901-z
,2021, 'Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition', npj Breast Cancer, 7, http://dx.doi.org/10.1038/s41523-021-00312-x
,2021, 'MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer', Frontiers in Oncology, 11, http://dx.doi.org/10.3389/fonc.2021.777867
,2021, 'Heart failure therapies for the prevention of her2-monoclonal antibody-mediated cardiotoxicity: A systematic review and meta-analysis of randomized trials', Cancers, 13, pp. 5527, http://dx.doi.org/10.3390/cancers13215527
,2021, 'Type 1 nuclear receptor activity in breast cancer: Translating preclinical insights to the clinic', Cancers, 13, pp. 4972, http://dx.doi.org/10.3390/cancers13194972
,2021, 'DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity', Cell Reports, 36, http://dx.doi.org/10.1016/j.celrep.2021.109722
,2021, 'A single-cell and spatially resolved atlas of human breast cancers', Nature Genetics, 53, pp. 1334 - 1347, http://dx.doi.org/10.1038/s41588-021-00911-1
,2021, 'The management of HER2-positive early breast cancer: Current and future therapies', Asia-Pacific Journal of Clinical Oncology, 17, pp. 3 - 12, http://dx.doi.org/10.1111/ajco.13655
,2021, 'Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review', Frontiers in Oncology, 11, http://dx.doi.org/10.3389/fonc.2021.701424
,2021, 'A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER plus advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.1050
,2021, 'acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.TPS1100
,2021, 'Australian real-world outcomes of ribociclib and aromatase inhibitor in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): Results from Kisqali Access Registry for Metastatic breast cancer in Australia (KARMA) collected alongside a medicine access program.', Journal of Clinical Oncology, 39, pp. e13018 - e13018, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e13018
,2021, 'Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.', Journal of Clinical Oncology, 39, pp. 1020 - 1020, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1020
,2021, 'Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.1017
,2021, 'Molecular biomarkers for contemporary therapies in hormone receptor‐positive breast cancer', Genes, 12, pp. 1 - 24, http://dx.doi.org/10.3390/genes12020285
,2021, 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27, pp. 310 - 320, http://dx.doi.org/10.1038/s41591-020-01168-7
,2021, 'CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care', Asia-Pacific Journal of Clinical Oncology, 17, pp. 3 - 14, http://dx.doi.org/10.1111/ajco.13555
,2021, 'Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer', , http://dx.doi.org/10.1101/2021.06.21.449340
,2020, 'Estrogen receptor positive breast cancer patient–derived xenograft models in translational research', Current Opinion in Endocrine and Metabolic Research, 15, pp. 31 - 36, http://dx.doi.org/10.1016/j.coemr.2020.10.004
,2020, 'Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer', Asia-Pacific Journal of Clinical Oncology, 16, pp. 3 - 14, http://dx.doi.org/10.1111/ajco.13461
,2020, 'Stromal cell diversity associated with immune evasion in human triple-negative breast cancer', EMBO Journal, 39, pp. embj2019104063, http://dx.doi.org/10.15252/embj.2019104063
,2020, 'Testosterone therapy considerations in oestrogen, progesterone and androgen receptor–positive breast cancer in a transgender man', Clinical Endocrinology, 93, pp. 355 - 357, http://dx.doi.org/10.1111/cen.14263
,2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', Breast Cancer Research, 22, pp. 87, http://dx.doi.org/10.1186/s13058-020-01318-2
,2020, 'MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer', , http://dx.doi.org/10.1101/2020.06.09.140921
,2020, 'Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer', Breast Cancer Research, 22, http://dx.doi.org/10.1186/s13058-020-01306-6
,2020, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', bioRxiv, http://dx.doi.org/10.1101/2020.06.04.135277
,2020, 'Single-cell analysis reveals diverse stromal subsets associated with immune evasion in triple-negative breast cancer', bioRxiv, http://dx.doi.org/10.1101/2020.06.04.135327
,2020, 'A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.', Journal of Clinical Oncology, 38, pp. 1023 - 1023, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1023
,2020, 'Targeting CDK2 in cancer: challenges and opportunities for therapy', Drug Discovery Today, 25, pp. 406 - 413, http://dx.doi.org/10.1016/j.drudis.2019.12.001
,2020, 'Cyclin E1 and cyclin E2 in ER+ breast cancer: Prospects as biomarkers and therapeutic targets', Endocrine-Related Cancer, 27, pp. R93 - R112, http://dx.doi.org/10.1530/ERC-19-0501
,2020, 'Window of opportunity treatment in breast cancer', ANZ Journal of Surgery, 90, pp. 34 - 40, http://dx.doi.org/10.1111/ans.15487
,2020, '9. Factors influencing the success rate of patient derived xenograft formation from breast cancer specimens', Pathology, 52, pp. S136 - S136, http://dx.doi.org/10.1016/j.pathol.2020.01.010
,2019, 'Expression of the interleukin-3/receptor complex by breast cancer cells promotes vascular mimicry via a PI3K-dependent mechanism and is associated with poor outcome', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p005
,2019, 'Single-cell transcriptomics reveals marked heterogeneity for intrinsic molecular subtype and cellular function in estrogen receptor positive breast cancer', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p045
,2019, 'Unravelling the role of cell plasticity in BrCa development and metastasis', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p040
,2019, 'Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary', Medical Journal of Australia, 211, pp. 224 - 229, http://dx.doi.org/10.5694/mja2.50280
,2019, 'The international academy of cytology yokohama system for reporting breast fine-needle aspiration biopsy cytopathology', Acta Cytologica, 63, pp. 257 - 273, http://dx.doi.org/10.1159/000499509
,2019, 'Immunoprofiling of breast cancer antigens using antibodies derived from local lymph nodes', Cancers, 11, http://dx.doi.org/10.3390/cancers11050682
,2019, 'Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer', Breast Cancer Research, 21, http://dx.doi.org/10.1186/s13058-019-1127-y
,2019, 'The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis', Breast Cancer Research and Treatment, 174, pp. 271 - 278, http://dx.doi.org/10.1007/s10549-018-5054-x
,2019, 'Non-canonical AR activity facilitates endocrine resistance in breast cancer', Endocrine-Related Cancer, 26, pp. 251 - 264, http://dx.doi.org/10.1530/ERC-18-0333
,